Epidemiology of benign prostatic hyperplasia

被引:25
|
作者
Robert, G. [1 ]
De La Taille, A. [2 ]
Descazeaud, A. [3 ]
机构
[1] CHU Bordeaux, Serv Urol, Bordeaux, France
[2] CHU Henri Mondor, AP HP, Serv Urol, Creteil, France
[3] CHU Limoges, Serv Urol, F-87042 Limoges, France
来源
PROGRES EN UROLOGIE | 2018年 / 28卷 / 15期
关键词
Benign prostatic hyperplasia; Epidemiology; Prevalence; Incidence; URINARY-TRACT SYMPTOMS; CLINICAL PROGRESSION; NATURAL-HISTORY; RISK-FACTORS; MEN; POPULATION; DUTASTERIDE; DYSFUNCTION; PREVALENCE; RETENTION;
D O I
10.1016/j.purol.2018.08.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. - Epidemiological data concerning benign prostatic hyperplasia are numerous but highly variable depending on the definition of the pathology that is selected and on the source of information used. The objective of this work was to present an inventory of the main epidemiological data available in France and worldwide. Material and method. - A literature review was conducted from the Pubmed database between 1990 and 2018. The MeshTerm "benign prostatic hyperplasia", "epidemiology", "prevalence", and "incidence" were used to identify key articles of interest. These references were analyzed on the basis of the titles and summaries and cross-referenced with the cited references. The main articles selected were discussed by the authors before being summarized in this work. Results. - The relationship between BPH, LUTS, OSV and increased prostate volume is difficult to establish. In the context of epidemiological studies, these difficulties have a major impact on the accuracy of the results that are proposed. Nevertheless, we see that global demographics and increased life expectancy are leading to a steady increase in the prevalence of this disease. The corresponding health expenditure is also increasing, but more rapidly, posing major public health issues. The analysis of national health system databases confirms the steady and significant increase in the number of patients medically treated while the number of operated patients remains stable for several years. Conclusion. - The number of patients treated for BPH-related LUTS is steadily increasing. The related health expenditures increase exponentially while their efficiency remains poorly assessed from a medico-economic point of view. Given the frequency of this pathology and the resulting financial stakes, improving the quality of life and preventing complications must remain the main objectives of the medical care offered to patients. (C) 2018 Published by Elsevier Masson SAS.
引用
收藏
页码:803 / 812
页数:10
相关论文
共 50 条
  • [11] Benign Prostatic Hyperplasia and Incident Cardiovascular Disease
    Suzuki, Yuta
    Kaneko, Hidehiro
    Okada, Akira
    Fujiu, Katsuhito
    Jo, Taisuke
    Takeda, Norifumi
    Tanaka, Atsushi
    Node, Koichi
    Morita, Hiroyuki
    Yasunaga, Hideo
    Komuro, Issei
    CIRCULATION JOURNAL, 2024, 88 (03) : 408 - 416
  • [12] Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: A 15-year longitudinal community-based study
    Fukuta, Fumimasa
    Masumori, Naoya
    Mori, Mitsuru
    Tsukamoto, Taiji
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (01) : 100 - 106
  • [13] Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990-2021
    Safiri, Saeid
    Sahin, Fikrettin
    Aletaha, Reza
    Sullman, Mark J. M.
    Shekarriz-Foumani, Reza
    Kolahi, Ali-Asghar
    BMC PUBLIC HEALTH, 2025, 25 (01)
  • [14] Benign Prostatic Hyperplasia
    Paolone, David R.
    CLINICS IN GERIATRIC MEDICINE, 2010, 26 (02) : 223 - +
  • [15] Benign Prostatic Hyperplasia
    Langan, Robert C.
    PRIMARY CARE, 2019, 46 (02): : 223 - +
  • [16] Clinical Management of Patient With Benign Prostatic Hyperplasia in Spain
    Cozar, J. M.
    Solsona, E.
    Brenes, F.
    Fernandez-Pro, A.
    Leon, F.
    Molero, J. M.
    Perez, J. F.
    Rodriguez, M. P.
    Huerta, A.
    Perez-Escolano, I.
    ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (10): : 580 - 588
  • [17] Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia
    Pisco, Joao M.
    Pinheiro, Luis C.
    Bilhim, Tiago
    Duarte, Marisa
    Mendes, Jorge R.
    Oliveira, Antonio G.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 22 (01) : 11 - 20
  • [18] Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system
    Bahia, Luciana Ribeiro
    Araujo, Denizar Vianna
    Pepe, Camila
    Trindade, Michelle
    Camargo, Caroline Mendonca
    Javaroni, Valter
    INTERNATIONAL BRAZ J UROL, 2012, 38 (05): : 595 - 605
  • [19] Behaviour modification and benign prostatic hyperplasia: replacement for medications
    Yap, Tet
    Emberton, Mark
    CURRENT OPINION IN UROLOGY, 2010, 20 (01) : 20 - 27
  • [20] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375